Real-World Comparison of Clopidogrel with Ticagrelor and Prasugrel In Patients with Chronic Coronary Disease Undergoing Atherectomy

Current societal guidelines reserve potent P2Y12 platelet receptor inhibitors (ticagrelor, prasugrel) for acute coronary syndrome (ACS) cases due to a paucity of evidence for their use in chronic coronary disease (CCD).1 Patients with CCD undergoing percutaneous coronary intervention (PCI) with adjunctive atherectomy represent a subset of patients with more complex coronary disease who may derive benefit from more potent platelet inhibition.2 Atherectomy is associated with an increased risk of microvascular injury, endothelial dysfunction, and platelet activation, which may contribute to the increased risk of thrombosis, myocardial infarction, and death seen in this patient cohort.

Source: The American Journal of Cardiology - February 22, 2024 Category: Cardiology Authors: Mahin R. Khan, Anoop N. Koshy, Richard Tanner, Serdar Farhan, Manish Vinayak, Ali Farooq, Samantha Sartori, Yihan Feng, Alessandro Spirito, Ayush Arora, Vishal Dhulipala, Vishal Kapur, Javed Suleman, Raman Sharma, Roxana Mehran, Annapoorna Kini, Samin K. Tags: Brief report Source Type: research